Akeso (HKG:9926) obtained approval for a supplementary new drug application for ivonescimab to treat non-small cell lung cancer from China's National Medical Products Administration, an April 25 Hong Kong bourse filing said.
The approval is for the indication of use of the drug as a monotherapy for the first-line treatment of PD-L1-positive (TPS 1%) non-small cell lung cancer patients.
This indication marks the second major approval for ivonescimab, according to the drug company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.